High frequency of expression of MAGE genes in human hepatocellular carcinoma

Liver

Volumn 19, Issue 2, 1999, Pages 110-114

  Chen, Chien Hung ^a   Huang, Guan Tarn ^a   Lee, Hsuan Shu ^a   Yang, Pei Ming ^a   Yan, Ming De ^a   Chen, Ding Shinn ^a   Sheu, Jin Chuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Immunotherapy; MAGE; Tumor antigen

Indexed keywords

GENE PRODUCT; MESSENGER RNA; TUMOR REJECTION ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032997107     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00019.x     Document Type: Article

References (32)

1. CHEN D S. Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: OKUDA K, ISHAK K G eds. Neoplasms of the liver. Tokyo: Springer-Verlag, 1987: 71-80.
2. SHEU J C, SUNG J L, CHEN D S, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56: 660-6.
3. VENOOK A P. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12: 1323-34.
4. CHEN C H, WU T C. Experimental vaccine strategies for cancer immunotherapy (Review). J Biomedical Sci 1998; 5: 231-52.
5. VAN DEN EYNDE B J, VAN DER BRUGGEN P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-93.
6. ROSENBERG S A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-82.
7. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
8. ITOH K, HAYASHI A, NAKAO M, HOSHINO T, SEKI N, SHICHIJO S. Human tumor rejection antigens MAGE. J Biochem 1996; 119: 385-90.
9. ITOH K, HAYASHI A, TOH Y, et al. Development of cancer vaccine by tumor rejection antigens. [Review]. Int Rev Immunol 1997; 14: 153-71.
10. YAMASHITA N, ISHIBASHI H, HAYASHIDA K, et al. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 1996; 24: 1437-40.
11. CHOMCZYNSKI P, SACCHI N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
12. INOUE H, MORI M, HONDA M, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995; 109: 1522-5.
13. YAMADA A, KATAOKA A, SHICHIJO S, et al. Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 1995; 64: 388-93.
14. SZNOL M, HOLMLUND J. Antigen-specific agents in development. [Review]. Semin Oncol 1997; 24: 173-86.
15. BRASSEUR F, RIMOLDI D, LIENARD D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 375-80.
16. CORRIAS M V, SCARUFFI P, OCCHINO M, DE BERNARDI B, TONINI G P, PISTOIA V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer 1996; 69: 403-7.
17. INOUE H, MORI M, LI J, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 1995; 63: 523-6.
18. QUILLIEN V, RAOUL J L, HERESBACH D, COLLET B, TOUJAS L, BRASSEUR F. Expression of MAGE genes in esophageal squamous-cell carcinoma. Anticancer Res 1997; 17: 387-91.
19. MORI M, INOUE H, MIMORI K, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996; 224: 183-8.
20. PATARD J J, BRASSEUR F, GIL-DIEZ S, et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995; 64: 60-4.
21. RUSSO V, TRAVERSARI C, VERRECCHIA A, MOTTOLESE M, NATALI P G, BORDIGNON C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 1995; 64: 216-21.
22. WEYNANTS P, LETHE B, BRASSEUR F, MARCHAND M, BOON T. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 1994; 56: 826-9.
23. EURA M, OGI K, CHIKAMATSU K, et al. Expression of the MAGE gene family in human hsad-and-neck squamous-cell carcinomas. Int J Cancer 1995; 64: 304-8.
24. TSUZURAHARA S, SATA M, IWAMOTO O, et al. Detection of MAGE-4 protein in the sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis. Jpn J Cancer Res 1997; 88: 915-8.
25. VAN DER BRUGGEN P, SZIKORA J P, BOEL P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-CW* 1601. Eur J Immunol 1994; 24: 2134-40.
26. TRAVERSARI C, VAN DER BRUGGEN P, LUESCHER I F, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-7.
27. VISSEREN M J, VAN DER BURG S H, VAN DER VOORT E I, et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997; 73: 125-30.
28. GAUGLER B, VAN DEN EYNDE B, VAN DER BRUGGEN P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolylic T lymphocytes. J Exp Med 1994; 179: 921-30.
29. TANAKA F, FUJIE T, TAHARA K, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997; 57: 4465-8.
30. REYNOLDS S R, ORATZ R, SHAPIRO R L, et al. Stimulation of CDS+ T cell responses to MAGE-3 and Melan A/ MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 1997; 72: 972-6.
31. NESTLE F O, ALIJAGIC S, GILLIET M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-33.
32. SONG W, KONG H L, CARPENTER H, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-56.